COVIran Barekat

COVIran Barekat vaccine production 03

COVID-19 vacir

COVIran Barekat is an Iranian-developed COVID-19 vaccine produced by Shifa Pharmed Industrial Group, a part of the larger conglomerate Barkat Pharmaceutical Group. The vaccine was developed in response to the global COVID-19 pandemic that began in late 2019, caused by the novel coronavirus SARS-CoV-2. COVIran Barekat is one of the first indigenous vaccines in the Islamic Republic of Iran, marking a significant milestone in the country's efforts to combat the pandemic.

Development and Approval

The development of COVIran Barekat started in early 2020, shortly after the global spread of COVID-19. The vaccine is based on the inactivated virus technology, a traditional method of vaccine development that involves growing the virus in culture, then inactivating or killing it so it cannot cause disease. This inactivated virus is then used to stimulate an immune response in the vaccinated individual without causing the disease.

In April 2021, COVIran Barekat received emergency use authorization from the Iranian Food and Drug Administration after undergoing several phases of clinical trials. These trials were designed to test the vaccine's safety, efficacy, and immunogenicity in a large number of participants.

Efficacy and Safety

Preliminary results from the clinical trials suggested that COVIran Barekat has an efficacy rate comparable to other COVID-19 vaccines available globally. The vaccine was reported to be effective in preventing COVID-19 infection, as well as reducing the severity of the disease in cases where infection occurred post-vaccination.

The safety profile of COVIran Barekat was generally favorable, with reported side effects being mild to moderate and similar to those observed with other COVID-19 vaccines. These included pain at the injection site, fatigue, headache, and fever.

Vaccination Campaign

Following its approval, COVIran Barekat was rolled out as part of Iran's national vaccination campaign against COVID-19. The government aimed to vaccinate a significant portion of the population to achieve herd immunity and curb the spread of the virus. The vaccine's development and deployment were seen as crucial steps in Iran's fight against the pandemic, especially considering the challenges posed by international sanctions that limited access to foreign-made vaccines.

International Recognition

While COVIran Barekat is primarily used within Iran, the country has expressed interest in offering the vaccine to other nations, especially those facing challenges in accessing COVID-19 vaccines. The international community has been cautious, awaiting further data on the vaccine's efficacy and safety from ongoing studies and real-world use.

Conclusion

COVIran Barekat represents a significant achievement for Iran in its efforts to combat the COVID-19 pandemic. The development of a domestically produced vaccine not only contributes to the global fight against the virus but also showcases the capabilities of Iranian science and technology in the field of vaccine development. As the world continues to battle COVID-19, the role of vaccines like COVIran Barekat in preventing the spread of the virus and saving lives cannot be understated.

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian